The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.

@article{Kesselheim2016TheHC,
  title={The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.},
  author={Aaron S. Kesselheim and Jerry Avorn and Ameet Sarpatwari},
  journal={JAMA},
  year={2016},
  volume={316 8},
  pages={
          858-71
        }
}
IMPORTANCE The increasing cost of prescription drugs in the United States has become a source of concern for patients, prescribers, payers, and policy makers. [...] Key MethodEVIDENCE We reviewed the peer-reviewed medical and health policy literature from January 2005 to July 2016 for articles addressing the sources of drug prices in the United States, the justifications and consequences of high prices, and possible solutions. Expand

Paper Mentions

Interventional Clinical Trial
Pheochromocytoma is a rare, catecholamine (ex. adrenaline) secreting tumor that requires preoperative alpha blockade to minimize intraoperative hemodynamic instability, thereby… Expand
ConditionsParaganglioma, Pheochromocytoma
InterventionDrug
Determinants of Market Exclusivity for Prescription Drugs in the United States
TLDR
The peer-reviewed medical and health policy literature was reviewed to identify studies that described the different types of patent protection and regulatory exclusivities that shield brand-name prescription drugs from competition and thus help to sustain high drug prices. Expand
Legal Challenges to State Drug Pricing Laws
TLDR
In this Viewpoint, the legal arguments that industry has raised in Maryland and Nevada are reviewed, 2 of the earliest states to encounter legal challenges to their drug price reform laws. Expand
Variation in Prescription Drug Prices by Retail Pharmacy Type
TLDR
This study partnered with GoodRx, a Web site for drug price comparison that leverages electronic claims adjudication and its relationships with large, national pharmacy benefit managers to provide nearly real-time data on drug prices, to systematically describe cash prices across different types of retail pharmacies throughout the United States. Expand
Comparing Generic Drug Markets in Europe and the United States: Prices, Volumes, and Spending
TLDR
It is indicated that there are opportunities for cost savings in generic drug markets in Europe and the United States, and governments should apply coherent supply‐ and demand‐side policies inGeneric drug markets. Expand
Rising Drug Costs for Neurologic Diseases.
TLDR
Clinicians should discuss the drug's value and the associated opportunity cost with patients and have an open discussion about patients' ability to financially tolerate the treatment, and clinical- and economic-based analyses from independent groups such as the Institute for Clinical and Economic Review can help physicians understand the value of drugs. Expand
Myths and Realities About Why Prescription Drug Prices in the United States Are So High
Prescription medications cost more in the USA than in any other developed country. The reasons for those high prices are contested between defenders of the pharmaceutical industry and critics. TheExpand
International Reference Pricing for Prescription Drugs in the United States: Administrative Limitations and Collateral Effects.
  • Leah Z Rand, A. Kesselheim
  • Medicine
  • Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
  • 2021
TLDR
US policymakers should consider international reference pricing as a supportive tool alongside other cost containment policies, such as value-based pricing or volume agreements, as well as recognize the collateral effects that the US adoption of international reference Pricing may have on other countries' prices. Expand
National trends in prescription drug expenditures and projections for 2017.
  • G. Schumock, E. Li, +5 authors L. Vermeulen
  • Medicine
  • American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • 2017
PURPOSE Historical trends and factors likely to influence future pharmaceutical expenditures are discussed, and projections are made for drug spending in 2017 in nonfederal hospitals, clinics, andExpand
Trajectories of Injectable Cancer Drug Costs After Launch in the United States.
TLDR
Anticancer drug costs may change substantially after launch, Regardless of competition or supplemental indications, there is a steady increase in costs of patented anticancer agents over time. Expand
Common Pharmaceutical Price and Cost Controls in the United Kingdom, France, and Germany: Lessons for the United States
  • M. Rodwin
  • Medicine
  • International journal of health services : planning, administration, evaluation
  • 2021
To identify pharmaceutical spending-control options for the United States, we analyzed the policies of the United Kingdom, France, and Germany, which encourage drugmakers to undertake innovationsExpand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 154 REFERENCES
Stemming the Escalating Cost of Prescription Drugs: A Position Paper of the American College of Physicians.
  • H. Daniel
  • Medicine
  • Annals of internal medicine
  • 2016
TLDR
Policy recommendations from the American College of Physicians to address the escalating costs of prescription drugs in the United States are reported and issues of regulatory approval, patents and intellectual property, assessment of value and cost-effectiveness, and health plan drug benefits are linked. Expand
Higher US branded drug prices and spending compared to other countries may stem partly from quick uptake of new drugs.
TLDR
It is found that depending on how prices were weighted for volume across the countries, brand-name prescription drug prices were 5-198 percent higher in the United States than in the other countries in all three study years. Expand
Options to Promote Competitive Generics Markets in the United States.
TLDR
In August, the price of the 62-year-old drug pyrimethamine (Daraprim), used to treat many potentially fatal parasitic infections, was increased practically overnight from $14 to $750 per tablet, prompting public outrage and a new round of proposals to address this issue. Expand
Payer and Policy Maker Steps to Support Value-Based Pricing for Drugs.
TLDR
Now that value-based prices can be determined for drugs, insurers and policy makers can consider steps toward a value-driven pricing system that does not require Medicare negotiation, price setting, or mandates. Expand
US pharmaceutical innovation in an international context.
TLDR
Higher prescription drug spending in the United States does not disproportionately privilege domestic innovation, and many countries with drug price regulation were significant contributors to pharmaceutical innovation. Expand
Why are cancer drugs so expensive in the United States, and what are the solutions?
TLDR
The high cost of cancer drugs, the reasons for these high prices, the implications for patients and the health care system, and potential solutions to the problem are discussed. Expand
'Government Patent Use': A Legal Approach To Reducing Drug Spending.
TLDR
It is proposed that the federal government invoke its power under an existing "government patent use" law to reduce excessive prices for important patent-protected medicines. Expand
Prescription drug cost sharing: associations with medication and medical utilization and spending and health.
TLDR
Pharmacy benefit design represents an important public health tool for improving patient treatment and adherence and increased cost sharing is highly correlated with reductions in pharmacy use, but the long-term consequences of benefit changes on health are still uncertain. Expand
High-cost generic drugs--implications for patients and policymakers.
TLDR
Having firm timelines in place will allow pharmaceutical companies to adjust more quickly to pricing anomalies, and to meet the GDUFA commitments to waive user fees. Expand
Variations in time of market exclusivity among top-selling prescription drugs in the United States.
TLDR
This study assessed how the market exclusivity period varied among drugs for different therapeutic areas and for other characteristics of top-selling prescription medications and obtained annual published lists of the top 200 drugs by sales. Expand
...
1
2
3
4
5
...